Pseudomonas aeruginosa Eradication: How Do We Measure Success?
Clinical Infectious Diseases SEP 1, 2015 V.61 N.5 P.716-718
Edith T. Zemanick and Theresa A. Laguna
1Department of Pediatrics, University of Colorado School of Medicine, Aurora
2Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis
Correspondence: Edith T. Zemanick, MD, MSCS, Department of Pediatrics, University of Colorado School of Medicine, 13123 E 16th Ave B-395, Aurora, CO 80045 (email@example.com).
Lung disease remains the major cause of morbidity and mortality for people living with cystic fibrosis (CF) .
Dysfunctional chloride conductance in the airways results in impaired mucus clearance, which drives a vicious cycle of infection, inflammation, and airway destruction.
Pseudomonas aeruginosa (Pa) is a bacterial pathogen largely feared by the CF community as its chronic presence is associated with lung damage, a more rapid decline in lung function, and earlier mortality [2–6]. Unfortunately, Pa in airway secretions will be cultured in 80% of people with CF by age 18 years.